Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $25.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price boosted by Barclays from $22.00 to $25.00 in a research report sent to investors on Wednesday morning, Benzinga reports. The firm currently has an overweight rating on the stock.

Other equities research analysts also recently issued research reports about the company. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. UBS Group increased their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Jefferies Financial Group increased their price objective on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Wednesday, July 10th. Finally, JPMorgan Chase & Co. increased their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Trading Down 1.9 %

NYSE:TEVA opened at $17.91 on Wednesday. The company has a market cap of $20.29 billion, a P/E ratio of -43.68, a P/E/G ratio of 1.32 and a beta of 0.88. The stock’s fifty day moving average price is $18.01 and its two-hundred day moving average price is $16.76. Teva Pharmaceutical Industries has a 1 year low of $8.10 and a 1 year high of $19.08. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.03. The firm had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. As a group, analysts expect that Teva Pharmaceutical Industries will post 2.33 EPS for the current year.

Insider Activity at Teva Pharmaceutical Industries

In related news, insider Eric A. Hughes sold 24,537 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the transaction, the insider now owns 45,060 shares of the company’s stock, valued at $777,285. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.55% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC grew its stake in shares of Teva Pharmaceutical Industries by 13.4% during the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock valued at $141,839,000 after buying an additional 1,031,400 shares during the last quarter. Maple Rock Capital Partners Inc. grew its stake in shares of Teva Pharmaceutical Industries by 68.3% during the first quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock valued at $61,568,000 after buying an additional 1,770,000 shares during the last quarter. Truist Financial Corp boosted its holdings in shares of Teva Pharmaceutical Industries by 7.0% during the second quarter. Truist Financial Corp now owns 3,885,251 shares of the company’s stock worth $63,135,000 after purchasing an additional 254,483 shares during the period. Iron Triangle Partners LP boosted its holdings in shares of Teva Pharmaceutical Industries by 113.1% during the first quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock worth $39,083,000 after purchasing an additional 1,469,864 shares during the period. Finally, Tri Locum Partners LP boosted its holdings in shares of Teva Pharmaceutical Industries by 15.1% during the second quarter. Tri Locum Partners LP now owns 2,550,307 shares of the company’s stock worth $41,442,000 after purchasing an additional 334,119 shares during the period. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.